Medeiros Rita, Rameix-Welti Marie-Anne, Lorin Valérie, Ribaud Patricia, Manuguerra Jean-Claude, Socie Gérard, Scieux Catherine, Naffakh Nadia, van der Werf Sylvie
Unité de Génétique Moléculaire des Virus Respiratoires, URA CNRS 1966, Université Paris 7 EA302, Centre National de Référence du virus influenzae (Région Nord), Institut Pasteur, Paris, France.
Antivir Ther. 2007;12(4):571-6.
Influenza A viruses are responsible for significant morbidity and mortality after bone marrow transplantation. Here we report failure of inhaled zanamivir treatment in a bone-marrow transplant recipient with pneumonia caused by an influenza A (H1N1) virus, although the influenza viruses isolated from bronchoalveolar lavages before and after treatment were clearly found to be sensitive to zanamivir using cell-based and enzymatic assays. Subsequent oral treatment with oseltamivir allowed complete recovery. Poor bioavailability of zanamivir in the peripheral lungs might have been limiting treatment efficacy in such an immunocompromised patient.
甲型流感病毒是骨髓移植后导致严重发病和死亡的原因。在此,我们报告了1例骨髓移植受者因甲型(H1N1)流感病毒引起肺炎,吸入扎那米韦治疗失败的病例,尽管在基于细胞和酶的检测中,治疗前后从支气管肺泡灌洗中分离出的流感病毒对扎那米韦均敏感。随后口服奥司他韦治疗使患者完全康复。扎那米韦在肺外周的生物利用度不佳,可能限制了其在这类免疫功能低下患者中的治疗效果。